331 results on '"Czubkowski, Piotr"'
Search Results
2. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial
3. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis
4. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency
5. SAT-021 Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival in an international multicentre cohort
6. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial
7. Outcomes of surgical management of familial intrahepatic cholestasis 1 and bile salt export protein deficiencies.
8. Awareness, referral and age at Kasai surgery for biliary atresia in Europe: A survey of the Quality‐of‐Care Task Force of ESPGHAN.
9. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
10. Genotype correlates with the natural history of severe bile salt export pump deficiency
11. The risk of cardiovascular complications in inflammatory bowel disease
12. The Impact of Severe Acute Respiratory Syndrome Coronavirus Type 2 on Children With Liver Diseases: A Joint European Society for Pediatric Gastroenterology, Hepatology and Nutrition and Society of Pediatric Liver Transplantation Position Paper
13. Anthropometric assessment: ESPGHAN quality of care survey from paediatric hospitals in 28 European countries.
14. CLASSICAL AUTOIMMUNE HEPATITIS AND THE IGG4-ASSOCIATED AUTOIMMUNE HEPATITIS IN PAEDIATRIC PATIENTS.
15. P1 Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database
16. Cholestasis Due to USP53 Deficiency
17. Cholestasis Due to USP53 Deficiency
18. Cardiovascular Risk Assessment in Children with Chronic Cholestatic Liver Diseases
19. Tissue Expression of Programmed Cell Death 1 Ligand1 (PD-L1) in Biopsies of Transplant Livers of Pediatric Patients as a Possible Marker of Acute Cellular Rejection
20. Analysis of safety in maralixibat-treated participants with progressive familial intrahepatic cholestasis: data from MARCH-PFIC
21. Efficacy and safety outcomes with odevixibat treatment: Pooled data from the phase 3 ASSERT and ASSERT-EXT studies in patients with Alagille syndrome
22. Analysis of long-term treatment effects of odevixibat on clinical outcomes in children with progressive familial intrahepatic cholestasis in odevixibat clinical studies vs external controls from the NAPPED database
23. Serum bile acids are associated with native liver survival in patients with Alagille syndrome: results from the GALA study group
24. Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): data from the MARCH-ON study
25. Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies
26. Oxidative Stress and Liver Transplantation
27. Natural History of Liver Disease in a Large International Cohort of Children with Alagille syndrome: Results from The <scp>GALA</scp> Study
28. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency
29. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis
30. Genotype-phenotype relationships of truncating mutations, p.E297G and p.D482G in bile salt export pump deficiency
31. The limited prognostic value of liver histology in children with biliary atresia
32. PEG 3350 Versus Lactulose for Treatment of Functional Constipation in Children: Randomized Study
33. PEG 3350 Versus Lactulose for Treatment of Functional Constipation in Children: Randomized Study
34. The relationship between 6-thioguanine levels and remission outcomes in children with autoimmune hepatitis. Single center experience
35. The Impact of a CMV Infection on the Expression of Selected Immunological Parameters in Liver Tissue in Children with Biliary Atresia
36. THU-291 - Serum bile acids are associated with native liver survival in patients with Alagille syndrome: results from the GALA study group
37. Acute Hepatitis of Unknown Etiology Among Young Children: Research Agenda by the ESPGHAN Hepatology Committee
38. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement
39. Relationships between decreases in serum bile acids, pruritus, and sleep disturbance scores with up to 72 weeks of odevixibat treatment in patients with progressive familial intrahepatic cholestasis
40. Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation
41. Analysis of quality of life, hepatic biochemical markers, and sleep in patients with progressive familial intrahepatic cholestasis who had a pruritus response with odevixibat treatment
42. Efficacy and safety of odevixibat over 72 weeks of treatment in patients with progressive familial intrahepatic cholestasis
43. EP1228: DISEASE BURDEN AND NATURAL HISTORY OF PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: BASELINE CLINICAL CHARACTERISTICS AMONG ODEVIXIBAT-TREATED PATIENTS IN THE PHASE 3 PEDFIC STUDIES
44. EP1229: RELATIONSHIPS BETWEEN DECREASES IN SERUM BILE ACIDS, PRURITUS, AND SLEEP DISTURBANCE SCORES WITH UP TO 72 WEEKS OF ODEVIXIBAT TREATMENT IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS
45. EP1232: ODEVIXIBAT EFFECTS ON CHOLESTASIS-RELATED PARAMETERS: ANALYSIS OF POOLED DATA FROM THE PEDFIC 1 AND PEDFIC 2 STUDIES IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS
46. Proceedings of ESPGHAN Monothematic Conference 2020: 'Acute Liver Failure in Children': Diagnosis and Initial Management.
47. Proceedings of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition Monothematic Conference, 2020: “Acute Liver Failure in Children”: Treatment and Directions for Future Research
48. Acute Hepatitis of Unknown Etiology Among Young Children: Research Agenda by the ESPGHAN Hepatology Committee
49. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial
50. Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.